VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Increase in Short Interest

VivoSim Labs, Inc. (NASDAQ:VIVS) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totaling 570,467 shares, an increase of 1,070.7% from the July 15th total of 48,730 shares. Based on an average daily trading volume, of 8,475,803 shares, the days-to-cover ratio is currently 0.1 days. Currently, 16.7% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, VivoSim Labs has an average rating of “Sell”.

VivoSim Labs Price Performance

Shares of VivoSim Labs stock opened at $0.35 on Wednesday. VivoSim Labs has a 1 year low of $0.31 and a 1 year high of $5.30. The firm has a market cap of $1.23 million, a PE ratio of -0.07 and a beta of 1.47. The company has a 50 day simple moving average of $0.81 and a two-hundred day simple moving average of $1.39.

VivoSim Labs (NASDAQ:VIVS) last released its quarterly earnings results on Tuesday, July 14th. The company reported ($2.21) EPS for the quarter. The company had revenue of $0.04 million during the quarter. VivoSim Labs had a negative return on equity of 277.62% and a negative net margin of 10,567.17%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP purchased a new stake in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs as of its most recent SEC filing. Hedge funds and other institutional investors own 8.23% of the company’s stock.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.